Data from the COV1001 phase I-IIa clinical trial reports humoral and cellular immune responses from 20 Ad26.COV2.S vaccinated individuals. It compares responses against the original SARS-CoV-2 strain WA1/2020 and the B.1.1.7, CAL.20C, P.1, and B.1.351 variants of concern. The dataset was authored by G Alter and shared via the paperswithcode platform.
Use Cases
- Compare neutralizing antibody titers against different SARS-CoV-2 variants based on the reported median fold reductions.
- Analyze the preservation of functional non-neutralizing antibody responses (e.g., antibody-dependent cellular phagocytosis) against variants like B.1.351.
- Evaluate T cell response comparability across variants based on CD8 and CD4 T cell data mentioned in the description.
Strengths
- Includes data from a controlled phase I-IIa clinical trial (COV1001).
- Reports specific, quantified immune response metrics, such as 5.0-fold and 3.3-fold lower neutralizing antibody titers against B.1.351 and P.1 variants.
- Measures multiple immune response types: humoral (neutralizing/binding antibodies) and cellular (T cell) responses.
Limitations
- Row count is unknown, which may limit suitability assessment.
- Column-level documentation is absent; field semantics must be inferred after download.
- Last update date is unknown; freshness unverified.
Provenance
- Source
- G Alter via paperswithcode platform.
- Collection Method
- Data likely originates from the COV1001 phase I-IIa clinical trial.
- Time Range
- Measurements include day 71 after vaccination.